Akums Drugs Q3 PAT Up 15% to Rs 66.3 cr | Business News
Akums Drugs and Pharmaceuticals reported a 15% rise in adjusted profit after tax to Rs 66.3 crore in Q3 FY25. The company also secured a 200-million euro contract for European markets.
New Delhi, Feb 7 (PTI) Akums Drugs and Pharmaceuticals on Friday reported a 15 per cent rise in adjusted profit after tax to Rs 66.3 crore in the quarter ended December 31, 2024.
The company had posted an adjusted PAT of Rs 57.5 crore in the same quarter last fiscal, Akums Drugs and Pharmaceuticals said in a regulatory filing.
Adjusted PAT is calculated as the profit for the quarter/period plus fair value changes to financial instruments less tax impact on account of business merger, the filing said.
"With our focus on establishing Akums' global CDMO footprint, we took a significant step by securing a 200-million euro contract. The contract involves manufacture and supply of products to be sold in European markets," Sanjeev Jain, Managing Director of Akums Drugs and Pharmaceuticals, said.
Total income of the company during the quarter under review stood at Rs 1,025 crore, as against Rs 1,091 crore in the year-ago period, it added.
Its Managing Director Sandeep Jain said, "We continue to be the manufacturing partners of choice for pharmaceutical companies. We have started to see volume green shoots in Q3 compared to Q2. We also in-licensed novel products of Triple hair and Caregen in the dermatology and metabolic segment to drive future growth.
The company had posted an adjusted PAT of Rs 57.5 crore in the same quarter last fiscal, Akums Drugs and Pharmaceuticals said in a regulatory filing.
Adjusted PAT is calculated as the profit for the quarter/period plus fair value changes to financial instruments less tax impact on account of business merger, the filing said.
"With our focus on establishing Akums' global CDMO footprint, we took a significant step by securing a 200-million euro contract. The contract involves manufacture and supply of products to be sold in European markets," Sanjeev Jain, Managing Director of Akums Drugs and Pharmaceuticals, said.
Total income of the company during the quarter under review stood at Rs 1,025 crore, as against Rs 1,091 crore in the year-ago period, it added.
Its Managing Director Sandeep Jain said, "We continue to be the manufacturing partners of choice for pharmaceutical companies. We have started to see volume green shoots in Q3 compared to Q2. We also in-licensed novel products of Triple hair and Caregen in the dermatology and metabolic segment to drive future growth.
You May Like To Read
TODAY'S MOST TRADED COMPANIES
- Company Name
- Price
- Volume
- Vodafone Idea L
- 7.34 ( -3.67)
- 63718866
- Standard Capital
- 0.56 ( 0.00)
- 20459336
- Guj. Toolroom Lt
- 1.65 ( -4.07)
- 16214575
- Srestha Finvest
- 0.55 ( -3.51)
- 14097480
- G G Engineering
- 0.97 ( -2.02)
- 14087015
MORE NEWS
© 2025 Rediff.com India Limited. All rights reserved. Disclaimer - Terms of Service - Privacy Policy - Feedback